November 2026– date –
-
Ascletis ASC30: Phase II Results for Oral GLP-1 in Type 2 Diabetes
BioPharma APAC China Overview Ascletis Pharma's oral small molecule GLP-1 receptor agonist, ASC30, achieved a placebo-adjusted HbA1c reduction of up to 1.7% and weight loss of up to 4.4% in a U.S. Phase II trial for type 2 diabetes. The ... -
XmAb819: Phase 1 Dose Selection and ccRCC Development Roadmap
Yahoo Finance (Business Wire) USA Overview Xencor has selected 400 mcg/kg as the proposed IV recommended Phase 3 dose (RP3D) for XmAb819, showing a 45.5% cORR and 82% 6-month PFS estimate. The company plans to discuss an accelerated FDA ... -
AZD8205: B7-H4 ADC Phase 1/2a results for solid tumors
BIOENGINEER.ORG USA Overview The first-in-human BLUESTAR trial of the B7-H4-directed antibody-drug conjugate AZD8205 (puxitatug samrotecan) demonstrated partial tumor responses in patients with advanced ovarian, endometrial, and breast c... -
Amgen Imdelltra: Phase 3 DeLLphi-305 results for ES-SCLC
BioSpace USA Overview Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced the risk of death by 58% compared to Imfinzi alone in first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC). The combin... -
ZW191 Phase 1 Data: FRα-Targeting ADC Efficacy in PROC Patients
BioSpace Canada Overview Zymeworks presented Phase 1 data for ZW191, showing a 64.5% confirmed objective response rate (cORR) at the 6.4 mg/kg dose in patients with high-grade serous platinum-resistant ovarian cancer (PROC). The ADC demo... -
CAMOLE-1: ML-driven discovery of selective MMP12 inhibitors
bioRxiv USA Overview Calico Life Sciences developed CAMOLE-1, a machine learning platform that utilizes an all-atom diffusion model to design potent and selective peptide inhibitors. The system successfully optimized an MMP12 inhibitor o... -
pro-DALAP Platform: Yeast-Based Oral Dual GLP-1/GIP Agonist Evaluation
medRxiv USA Overview Researchers developed a Saccharomyces cerevisiae-based platform to deliver pro-DALAP, a dual GLP-1/GIP receptor agonist, via oral enteric-coated capsules. While in vitro and rat toxicology studies showed functionalit... -
Light-Responsive LNPs: VEGFA Editing for CNV Suppression
bioRxiv Overview Researchers developed a light-responsive lipid nanoparticle (LNP) platform to deliver Cas9 RNP for the spatially controlled editing of the VEGFA gene. In a rat model of choroidal neovascularisation (CNV), a single intrav... -
LNP Morphology: Impact of Shape on mRNA Transfection Performance
bioRxiv Overview Research indicates that the shape and internal architecture of lipid nanoparticles (LNP) significantly determine the magnitude and duration of mRNA transfection. Non-spherical, vesicular morphologies exhibit substantiall... -
XPENG Solid-State Battery: IRON Humanoid Robot Specs and Roadmap
Gasgoo China Overview XPENG has commenced small-scale production of a dedicated solid-state battery for its IRON humanoid robot, offering 30% more capacity and 30% less weight than conventional liquid lithium batteries. This development ...
